AstraZeneca Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	4,893	5,711	5,488	5,840	6,166	6,329
Short-Term Investments	75	-	-	-	64	53
Trading Asset Securities	-	8	37	20	14	16
Cash & Short-Term Investments	4,968	5,719	5,525	5,860	6,244	6,398
Cash Growth	-30.11%	3.51%	-5.72%	-6.15%	-2.41%	-20.37%
Accounts Receivable	14,330	10,237	8,302	8,407	7,212	6,031
Other Receivables	1,659	4,064	4,792	3,528	2,711	2,764
Receivables	15,989	14,301	13,094	11,935	9,923	8,795
Inventory	6,932	6,557	5,288	5,424	4,699	8,983
Prepaid Expenses	-	2,034	1,737	1,617	1,329	1,512
Restricted Cash	-	22	129	102	162	-
Other Current Assets	76	90	54	116	236	556
Total Current Assets	27,965	28,723	25,827	25,054	22,593	26,244
Property, Plant & Equipment	16,300	14,703	11,647	10,502	9,449	10,171
Long-Term Investments	2,916	2,525	1,900	1,677	1,142	1,262
Goodwill	21,181	21,242	21,025	20,048	19,820	19,997
Other Intangible Assets	37,723	37,846	37,177	38,089	39,307	42,387
Long-Term Deferred Tax Assets	6,487	5,819	5,347	4,718	3,263	4,330
Other Long-Term Assets	3,261	3,216	1,112	1,031	909	972
Total Assets	115,833	114,074	104,035	101,119	96,483	105,363
Accounts Payable	22,893	3,820	3,640	3,267	2,550	2,824
Accrued Expenses	-	19,299	16,088	15,845	13,514	12,358
Short-Term Debt	2,949	644	330	515	350	411
Current Portion of Long-Term Debt	2,967	2,541	2,057	5,603	5,924	2,248
Current Portion of Leases	426	382	339	271	228	233
Current Income Taxes Payable	1,468	1,084	1,406	1,584	896	916
Current Unearned Revenue	-	144	126	149	182	1,181
Other Current Liabilities	850	2,703	3,880	3,308	2,649	2,423
Total Current Liabilities	31,553	30,617	27,866	30,542	26,293	22,594
Long-Term Debt	23,686	24,715	26,621	22,403	23,908	29,717
Long-Term Leases	2,322	1,421	1,113	857	725	754
Long-Term Unearned Revenue	-	55	-	7	14	26
Pension & Post-Retirement Benefits	852	1,105	1,330	1,520	1,168	2,454
Long-Term Deferred Tax Liabilities	3,463	3,500	3,305	2,844	2,944	6,206
Other Long-Term Liabilities	3,587	3,942	2,929	3,780	4,373	4,325
Total Liabilities	65,463	65,355	63,164	61,953	59,425	66,076
Common Stock	388	388	388	388	387	387
Additional Paid-In Capital	35,282	35,266	35,226	35,188	35,155	35,126
Retained Earnings	12,592	12,599	7,229	4,516	3,120	3,644
Comprehensive Income & Other	2,033	414	-2,057	-949	-1,625	111
Total Common Equity	50,295	48,667	40,786	39,143	37,037	39,268
Minority Interest	75	52	85	23	21	19
Shareholders' Equity	50,370	48,719	40,871	39,166	37,058	39,287
Total Liabilities & Equity	115,833	114,074	104,035	101,119	96,483	105,363
Total Debt	32,350	29,703	30,460	29,649	31,135	33,363
Net Cash (Debt)	-27,382	-23,984	-24,935	-23,789	-24,891	-26,965
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-17.52	-15.35	-15.95	-15.23	-15.96	-18.90
Filing Date Shares Outstanding	1,551	1,551	1,551	1,550	1,550	1,549
Total Common Shares Outstanding	1,551	1,551	1,551	1,550	1,550	1,549
Working Capital	-3,588	-1,894	-2,039	-5,488	-3,700	3,650
Book Value Per Share	32.43	31.38	26.30	25.25	23.90	25.34
Tangible Book Value	-8,609	-10,421	-17,416	-18,994	-22,090	-23,116
Tangible Book Value Per Share	-5.55	-6.72	-11.23	-12.25	-14.25	-14.92
Land	-	7,240	6,580	6,469	5,440	6,377
Machinery	-	10,320	8,854	8,704	7,556	7,903
Construction In Progress	-	4,740	2,789	2,045	2,653	2,728